Lakewood-Amedex to Present Nu-3 Phase 2 Gel Strategy at June 25 Forum
LABT•Lakewood-Amedex Biotherapeutics will present its growth strategy and lead Bisphosphocin® candidate Nu-3 at the Life Sciences Virtual Investor Forum on June 25, 2026. Nu-3, a topical gel for infected diabetic foot ulcers, is advancing into Phase 2 clinical trials targeting a large underserved patient population.
1. Forum Presentation Details
Lakewood-Amedex Biotherapeutics will present at the Life Sciences Virtual Investor Forum on June 25, 2026 at 11:30 AM EDT, where CEO Kelvin Cooper, Ph.D., will outline the company’s growth strategy and development roadmap.
2. Lead Candidate Nu-3 Overview
Nu-3 is a topical gel developed for mild infected diabetic foot ulcers using the Bisphosphocin® class’s rapid, broad-spectrum antimicrobial mechanism; the candidate is scheduled to enter Phase 2 clinical trials later this year.
3. Addressing Unmet Clinical Needs
Mild iDFU impacts millions worldwide and can lead to serious infections and amputations; Lakewood-Amedex emphasizes Nu-3’s novel mode of action as a potential solution for a large, underserved patient population.
